Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PURE Bioscience (PURE : OTC)
 
 • Company Description   
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 20,174 shares
Shares Outstanding: 130.02 (millions)
Market Capitalization: $9.10 (millions)
Beta: 0.34
52 Week High: $0.10
52 Week Low: $0.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.91% -3.39%
12 Week -8.97% -6.91%
Year To Date 66.67% 51.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
771 JAMACHA ROAD #512
-
EL CAJON,CA 92019
USA
ph: 619-596-8600
fax: 619-596-8790
melliott@purebio.com http://www.purebio.com
 
 • General Corporate Information   
Officers
Jeff Kitchell - President; Chief Executive Officer
Ivan Chen - Chairman of the Board
Mark Elliott - Vice President; Finance;Principal Financial and Ac
Tom Myers - Director
David Rendall - Director

Peer Information
PURE Bioscience (BJCT)
PURE Bioscience (CADMQ)
PURE Bioscience (APNO)
PURE Bioscience (UPDC)
PURE Bioscience (IMTIQ)
PURE Bioscience (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 74621T209
SIC: 2890
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 07/01/26
Next Expected EPS Date: 12/21/26
Share - Related Items
Shares Outstanding: 130.02
Most Recent Split Date: 8.00 (0.13:1)
Beta: 0.34
Market Capitalization: $9.10 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 12/21/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 3.93
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: -61.43%
vs. Previous Quarter: 30.43%
ROE
10/31/26 - -
07/31/26 - -
04/30/26 - -
ROA
10/31/26 - -
07/31/26 - -210.20
04/30/26 - -321.74
Current Ratio
10/31/26 - -
07/31/26 - 0.27
04/30/26 - 0.42
Quick Ratio
10/31/26 - -
07/31/26 - 0.23
04/30/26 - 0.36
Operating Margin
10/31/26 - -
07/31/26 - -107.12
04/30/26 - -109.59
Net Margin
10/31/26 - -
07/31/26 - -107.12
04/30/26 - -109.59
Pre-Tax Margin
10/31/26 - -
07/31/26 - -107.12
04/30/26 - -65.45
Book Value
10/31/26 - -
07/31/26 - -0.05
04/30/26 - -0.04
Inventory Turnover
10/31/26 - -
07/31/26 - 4.38
04/30/26 - 4.67
Debt-to-Equity
10/31/26 - -
07/31/26 - -
04/30/26 - -
Debt-to-Capital
10/31/26 - -
07/31/26 - -
04/30/26 - -
 

Powered by Zacks Investment Research ©